Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 3—March 2016
CME ACTIVITY - Synopsis

Patient Report and Review of Rapidly Growing Mycobacterial Infection after Cardiac Device Implantation

Varun K. PhadkeComments to Author , David S. Hirsh, and Neela D. Goswami
Author affiliations: Emory University, Atlanta, Georgia, USA

Cite This Article

Introduction

CME Logo

Medscape, LLC is pleased to provide online continuing medical education (CME) for this journal article, allowing clinicians the opportunity to earn CME credit.

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at http://www.medscape.org/journal/eid; (4) view/print certificate.

Release date: January 18, 2016; Expiration date: January 18, 2017

Learning Objectives

Upon completion of this activity, participants will be able to:

•     Determine the clinical and etiologic considerations regarding mycobacterial cardiac implantable electronic device infections, based on a case report and review

•     Identify antibiotic resistance of mycobacterial cardiac implantable electronic device infections

•     Evaluate management of mycobacterial cardiac implantable electronic device infections

CME Editor

Rhonda Ray, PhD, Copyeditor, Emerging Infectious Diseases. Disclosure: Rhonda Ray, PhD, has disclosed no relevant financial relationships.

CME Author

Laurie Barclay, MD, freelance writer and reviewer, Medscape, LLC. Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.

Authors

Disclosures: Varun K. Phadke, MD; and Neela D. Goswami, MD, MPH, have disclosed no relevant financial relationships. David S. Hirsh, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for Biotronik.

Top

Abstract

Mycobacterial infections resulting from cardiac implantable electronic devices are rare, but as more devices are implanted, these organisms are increasingly emerging as causes of early-onset infections. We report a patient with an implantable cardioverter-defibrillator pocket and associated bloodstream infection caused by an organism of the Mycobacterium fortuitum group, and we review the literature regarding mycobacterial infections resulting from cardiac device implantations. Thirty-two such infections have been previously described; most (70%) were caused by rapidly growing species, of which M. fortuitum group species were predominant. When managing such infections, clinicians should consider the potential need for extended incubation of routine cultures or dedicated mycobacterial cultures for accurate diagnosis; combination antimicrobial drug therapy, even for isolates that appear to be macrolide susceptible, because of the potential for inducible resistance to this drug class; and the arrhythmogenicity of the antimicrobial drugs traditionally recommended for infections caused by these organisms.

Infection is an uncommon but potentially devastating complication of cardiac implantable electronic device (CIED) implantation (1). Staphylococcal species cause most of these infections, followed by other pyogenic bacteria (1). CIED infections caused by mycobacteria have been reported infrequently; most of these infections result from the rapidly growing nontuberculous mycobacteria. We report a patient with an infection caused by a rapidly growing mycobacterium (RGM) in the Mycobacterium fortuitum group that developed following placement of an implantable cardioverter-defibrillator (ICD). We also review the published literature of cardiac device–associated infections caused by mycobacteria, focusing particularly on RGM.

Patient Report

A 60-year-old man with chronic systolic heart failure, emphysema, and hepatitis C infection was admitted to Grady Memorial Hospital (Atlanta, Georgia, USA) with 2 days of purulent drainage from his ICD pocket site. Just before his admission, pain had developed, followed by spontaneous dehiscence (i.e., separation of the surgical incision along the suture line) of the pocket. He reported no fever or constitutional symptoms. Two months earlier, a single-chamber ICD had been inserted uneventfully in his left prepectoral region after he had an episode of ventricular fibrillation that led to cardiac arrest. At the time of device implantation, he had been receiving intravenous vancomycin and piperacillin/tazobactam for concomitant hospital-acquired pneumonia, and he was prescribed oral cephalexin for 5 days after the procedure. During outpatient follow-up visits at weeks 2 and 4 after device insertion, the patient’s wound was noted as unremarkable.

At the time of the new admission, the patient was afebrile with unremarkable vital signs. Physical examination showed mild, nontender edema over the ICD pocket; a 1-cm, shallow ulceration of the incision site; scant serous drainage; and minimal surrounding erythema. The patient had no peripheral stigmata of infective endocarditis, and the remainder of the examination was unremarkable. Laboratory studies showed a normal leukocyte count (5,500 cells/μL) with a slight (70%) neutrophil predominance. Blood cultures were collected, and he was started empirically on intravenous vancomycin for a suspected pocket infection. Transthoracic echocardiography was performed and showed no valvular vegetations. A transesophageal echocardiogram was deferred because of considerable laryngeal stenosis caused by traumatic endotracheal intubation at the time of his recent cardiac arrest.

Figure

Thumbnail of Photographs of the cardiac implantable electronic device pocket site for a 60-year-old man in whom infection developed at the implantation site of a cardiac implantable electronic device, Atlanta, Georgia, USA. A) Device pocket site after explantation. The wound was closed with pledged Ethibond sutures (Ethicon, Somerville, NJ, USA), and a Jackson-Pratt drain (closed-suction drainage system consisting of an internal drain connected by plastic tubing to a flexible bulb) was tunneled

Figure. Photographs of the cardiac implantable electronic device pocket site for a 60-year-old man in whom infection developed at the implantation site of a cardiac implantable electronic device, Atlanta, Georgia, USA. A)...

On hospital day 2, the entire device, including the ICD generator and leads, was removed and sent for culture. Purulent fluid and necrotic tissue were noted in the pocket during explantation, and a drain was left in place at the time of wound closure (Figure, panel A). Gram stain of the pocket exudate showed beaded gram-positive rods. Within 5 days, the generator pocket tissue culture and 1 of 2 sets of blood cultures were growing an aerobic, gram-positive rod that also appeared beaded on Gram stain. Culture of the lead tip remained sterile. Because of the Gram-stain appearance of the blood culture isolate, an acid-fast stain was performed in the microbiology laboratory, and results showed the organism to be acid fast. At the request of the inpatient infectious diseases consultation service, the isolate was subcultured to mycobacterial growth media and was identified as an RGM. An HIV test result was negative.

The patient’s antimicrobial drug regimen was empirically changed to intravenous cefoxitin, oral ciprofloxacin, and oral clarithromycin, a combination selected because of a clinical suspicion of M. fortuitum infection, surmised from the limited literature on RGM-associated CIED. Because of uncertainty about the capacity for outpatient therapeutic drug monitoring and because the patient had undergone surgical debridement and was thought to be clinically improved at the time of discharge, intravenous aminoglycoside therapy was deferred pending species identification and test results regarding antimicrobial drug susceptibility. A baseline electrocardiogram obtained before initiation of antimicrobial drugs showed a corrected QT interval (i.e., duration from start of Q wave to end of T wave in the heart’s electrical cycle) of 511 ms (reference <430 ms).

One week after device extraction, a computed tomography scan of the patient’s chest was performed, and results showed a residual, subclinical, peripherally enhancing, 2.7 × 1.0–cm collection of air and fluid over the left pectoralis muscle. Immediate device reimplantation was deferred. He was discharged on hospital day 14 with a wearable cardioverter-defibrillator to use until his physicians believed that device reimplantation was safe. The therapeutic plan at discharge was for at least 6 months of antimicrobial drug therapy, beginning with the cefoxitin, ciprofloxacin, and clarithromycin regimen and subsequently tailored to the organism and susceptibility profile when these data became available.

Five weeks after device removal, the patient returned for outpatient follow-up and reported full adherence to his prescribed antimicrobial drug regimen. On examination, most of the wound over the previous device pocket had healed, but localized dehiscence and ongoing purulent drainage was evident (Figure, panel B). He was referred to plastic surgery for ongoing management of his wound. Identification and antimicrobial drug susceptibilities of the organism were still pending, so his antimicrobial drug regimen was not changed. Unfortunately, he was lost to follow-up; 2 months later, he discontinued use of his wearable cardioverter-defibrillator and died of out-of-hospital cardiac arrest.

By use of high-performance liquid chromatography, the patient’s isolate was identified as a Mycobacterium fortuitum group organism. Further genetic testing for species-level identification was not performed. The following susceptibilities were identified: cefoxitin intermediate (MIC 64 μg/mL), ciprofloxacin susceptible (MIC <0.12 μg/mL), and clarithromycin resistant (MIC 8 μg/mL after 14 days of incubation) (Table 1).

Discussion

The RGM species are ubiquitous environmental organisms that have been isolated from soil, food, natural and municipal water, various plants and animals, and hospital surfaces (3). These organisms are not believed to be permanent members of the human bacterial flora but often become transient colonizers after frequent exposure. The most commonly encountered RGM species in clinical practice are M. abscessus, M. chelonae, and M. fortuitum, but >100 species have been identified (3). These organisms are capable of growth on standard mycobacterial (e.g., Middlebrook 7H11 or Lownstein-Jensen) and routine bacteriologic (e.g., sheep’s blood and MacConkey agar) growth media. However, colonies may take >5 days to appear on standard media, exceeding the incubation time of routine cultures in many clinical microbiology laboratories. Even when growth is observed, these organisms often appear as beaded gram-positive bacilli on routine Gram stain and may be misidentified as contaminants (4). Therefore, a high index of suspicion for a potential RGM infection is needed for an accurate diagnosis.

Despite increasing recognition that these organisms can cause infections associated with prosthetic devices and surgical sites, RGM infections complicating implanted cardiac devices are still uncommon. We searched the available literature using PubMed with no starting date restrictions through March 31, 2015, and identified only 32 previously reported cases of CIED infections caused by any mycobacterial species. Including our patient, 23 (70%) of 33 reported infections were caused by an RGM species (524) (Table 2). We found 2 reports of CIED infections caused by M. avium complex (26,27) and 8 reports of infections caused by M. tuberculosis complex organisms (2833). Of the 23 RGM infections, 21 (91%) were reported in the past 10 years, a trend likely resulting from improvements in microbiologic techniques and increased recognition of these organisms as causative pathogens. Mean age of case-patients with RGM infections was 65.4 years, consistent with age trends for CIED implantation. Sixteen (70%) case-patients had infections associated with permanent pacemakers. Among 21 case-patients for which time of onset was reported, 5 (24%) infections developed >6 months after the most recent device manipulation. Although cardiac devices can become secondarily infected because of seeding from incidental bloodstream infections, the RGM species are uncommon causes of bacteremia. Instead, the source of early-onset CIED infections is more likely inoculation of the organism into the pocket at the time of the implantation procedure. This source contrasts with the probable source for the 8 reported CIED infections caused by M. tuberculosis complex. Manifesting >11 months after device manipulation, these infections more likely resulted from reactivation disease, mycobacteremia, and secondary seeding of the device.

The most commonly isolated organisms have been in the M. fortuitum group, which account for ≈50% of mycobacterial CIED infections in patients and nearly two thirds of infections caused by an RGM species. The M. fortuitum group has historically included M. fortuitum and M. peregrinum, although M. mageritense and others have also been proposed as members of this group (3). The preponderance of M. fortuitum infections among patients with cardiac device implantations mirrors trends observed for poststernotomy (34) and postaugmentation mammoplasty (35) infections caused by RGM. Although most skin and soft tissue infections caused by RGM, particularly after surgical or nonsurgical trauma, result from M. fortuitum (3), this organism is not considered a normal skin commensal. Sources of these infections are instead thought to be largely environmental (3). Nevertheless, among all skin and soft tissue infections caused by RGM, those on the chest or back seem more likely to result from M. fortuitum than from other RGM species (36).

Another trend we observed was that 11 (48%) of the 23 patients with a RGM infection had associated mycobacteremia (5 had no reported blood culture results). This finding indicates that the infection had spread beyond the device pocket to the intravascular component of the CIED system, suggesting endovascular infection. In the 13 (57%) patients for which both blood culture results and echocardiographic findings were reported, 4 (31%) had device-related endocarditis, as defined by the Duke criteria (9,18,2325). Three of these 4 patients fulfilled clinical criteria for infective endocarditis on the basis of echocardiographic findings; the fourth had no echocardiographic abnormalities but fulfilled pathologic criteria on the basis of isolation of the organism in an operative culture. This patient was the only one with valvular endocarditis among all the reports in our review (18).

Conversely, in 4 patients, including the patient described in this article, mycobacteremia was detected in the absence of echocardiographic abnormalities. The patient we describe had an unremarkable transthoracic echocardiogram, but a transesophageal echocardiogram could not be performed for definitive evaluation of CIED-related endocarditis. Overall, the low rates of valvular endocarditis or disseminated infection suggest that CIED infections caused by an RGM behave similarly to catheter-related bloodstream infections caused by these organisms (37), although severe complications of CIED infections associated with bacteremia have rarely been described (18,23).

The Clinical and Laboratory Standards Institute recommends routine broth microdilution susceptibility testing of all RGM isolates against amikacin, cefoxitin, ciprofloxacin, clarithromycin, doxycycline, imipenem, and sulfamethoxazole (or trimethoprim/sulfamethoxazole), but newer agents (e.g., linezolid, moxifloxacin, and tigecycline) also frequently show in vitro activity against these organisms (2). Of all RGMs, the M. fortuitum group is traditionally considered the most susceptible to antimicrobial drugs, with isolates frequently being susceptible to many agents tested. However, current guidelines by the American Thoracic Society and the Infectious Diseases Society of America recommend therapy with >2 active drugs for several months for optimal results. The isolate of the patient in this report showed resistance to several tested agents, including clarithromycin (Table 1). Among patients with CIED infections caused by M. fortuitum group organisms for which susceptibility data were reported, only 4 (including the patient reported in this article) had macrolide resistance. A previous review of the RGM similarly noted that most M. fortuitum clinical isolates were macrolide susceptible by in vitro methods (3).

Genetic studies published after that review revealed that most, if not all, M. fortuitum isolates also harbor an M. fortuitum rRNA methylase gene, termed erm(39), that, if active, can confer macrolide resistance (38,39). Although the clinical significance of this potential mechanism of inducible macrolide resistance is unclear, particularly in strains in which the gene is inactive at baseline, this finding has led many experts to advise caution to clinicians who consider prescribing macrolide-based regimens for serious M. fortuitum infections, even when the isolate is reported as susceptible to macrolides on the basis of broth microdilution methods (2). Nevertheless, in most reported CIED infections caused by macrolide-susceptible M. fortuitum group organisms, a macrolide and fluoroquinolone combination has been used successfully. We speculate that the patient described in this article experienced delayed wound healing resulting from inadequate activity of the empirical antimicrobial regimen against his isolate.

Given the recommended antimicrobial drug regimens for infections caused by an RGM, cardiac device infections resulting from these organisms can pose a unique therapeutic dilemma. On the one hand, the propensity to biofilm formation makes these organisms difficult to eradicate with antimicrobial drug therapy alone. Consequently, most experts advocate an extended course of antimicrobial drugs combined with device removal (37), the strategy used in all but 3 (13%) of the 23 previously described case-patients with infections caused by an RGM. On the other hand, some of the most active agents against this group of organisms belong to the macrolide or fluoroquinolone classes, which are both types of antimicrobial drugs with potential proarrhythmic effects (39,40). An antimicrobial drug combination that has the potential to precipitate arrhythmias becomes problematic in patients being considered for device removal and having a preexisting risk for conduction abnormalities (caused by an underlying conduction disease, cardiomyopathy, or concomitant proarrhythmic medications). The patient we describe was noted to have a prolonged corrected QT interval before the start of macrolide or fluoroquinolone therapy, a circumstance that made selection of an appropriate empirical antimicrobial regimen challenging. This patient highlights the importance of expedited antimicrobial drug susceptibility testing for managing these infections, including evaluation of newer antimicrobial drugs with fewer direct arrhythmogenic effects than those resulting from macrolides or fluoroquinolones.

Infections occurring after implantation of cardiac devices and caused by nontuberculous mycobacteria are uncommon, but as more devices are implanted, such infections are likely to be more frequently reported. Our patient illustrates many of the common clinical features of postimplantation CIED infections caused by RGMs, including early onset (<6 months from the most recent manipulation of the device) of disease, initial identification of the organism as a gram-positive bacillus, and isolation of a M. fortuitum group organism as the causative pathogen. In addition, this patient highlights several unique issues that warrant further investigation, such as reliability of macrolide therapy for M. fortuitum group infections and safety of long-term macrolide and fluoroquinolone use in patients with a preexisting high risk for serious arrhythmias.

Dr. Phadke is an infectious diseases fellow at Emory University in Atlanta. His research interests include vaccine-preventable diseases.

Top

Acknowledgments

The authors thank Makoto Mori for his assistance with translation of a case report in the literature.

V.K.P. is supported by the Emory Vaccinology Training Program under award no. T32AI074492 from the National Institute of Allergy and Infectious Diseases. The content of this review is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health.

Top

References

  1. Uslan  DZ, Sohail  MR, St Sauver  JL, Friedman  PA, Hayes  DL, Stoner  SM, Permanent pacemaker and implantable cardioverter defibrillator infection: a population-based study. Arch Intern Med. 2007;167:66975. DOIPubMed
  2. Clinical and Laboratory Standards Institute. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard. CLSI Document M24–A2. Wayne (PA); 2011.
  3. Brown-Elliott  BA, Wallace  RJ Jr. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev. 2002;15:71646. DOIPubMed
  4. von Graevenitz  A, Punter-Streit  V. Failure to recognize rapidly growing mycobacteria in a proficiency testing sample without specific request—a wider diagnostic problem? Eur J Epidemiol. 1998;14:51920. DOIPubMed
  5. Cutay  AM, Horowitz  HW, Pooley  RW, Van Horn  K, Wormser  GP. Infection of epicardial pacemaker wires due to Mycobacterium abscessus. Clin Infect Dis. 1998;26:5201. DOIPubMed
  6. Verghese  S, Mullaseri  A, Padmaja  P, Subhadra  AC, Cherian  KM. Pacemaker implant site infection caused by atypical mycobacteria. Indian Heart J. 1998;50:2012.PubMed
  7. Kessler  AT, Kourtis  AP. Mycobacterium abscessus as a cause of pacemaker infection. Med Sci Monit. 2004;10:CS602.PubMed
  8. Hemmersbach-Miller  M, Cardenes-Santana  MA, Conde-Martel  A, Bolanos-Guerra  JA, Campos-Herrero  MI. Cardiac device infections due to Mycobacterium fortuitum. Can J Infect Dis Med Microbiol. 2005;16:1835.PubMed
  9. Sharma  S, Tleyjeh  IM, Espinosa  RE, Costello  BA, Baddour  LM. Pacemaker infection due to Mycobacterium fortuitum. Scand J Infect Dis. 2005;37:667. DOIPubMed
  10. Short  WR, Emery  C, Bhandary  M, O’Donnell  JA. Misidentification of Mycobacterium peregrinum, the causal organism of a case of bacteremia and automatic implantable cardioverter defibrillator-associated infection, due to its unusual acid-fast staining characteristics. J Clin Microbiol. 2005;43:20157. DOIPubMed
  11. Pastor  E, Luz Andreu  A, Llombart  M, Chiner  E. Mycobacterium fortuitum: a rare cause of pacemaker infection [in Spanish]. Enferm Infecc Microbiol Clin. 2006;24:1367. DOIPubMed
  12. Toda  H, Sato  K, Iimori  M, Yamazumi  T, Furuta  I, Satoh  A, A case of Mycobacterium goodii infection with isolation from blood and a pacemaker lead [in Japanese]. Kansenshogaku Zasshi. 2006;80:2626. DOIPubMed
  13. Giannella  M, Valerio  M, Franco  JA, Marin  M, Bouza  E, Munoz  P. Pacemaker infection due to Mycobacterium fortuitum: the role of universal 16S rRNA gene PCR and sequencing. Diagn Microbiol Infect Dis. 2007;57:3379. DOIPubMed
  14. Simmon  KE, Pounder  JI, Greene  JN, Walsh  F, Anderson  CM, Cohen  S, Identification of an emerging pathogen, Mycobacterium massiliense, by rpoB sequencing of clinical isolates collected in the United States. J Clin Microbiol. 2007;45:197880. DOIPubMed
  15. Siu  CW, Cheng  LC, Woo  PC, Lau  CP, Tse  HF. A patient with relapsing pacemaker infection due to “Gram-positive bacilli”. Int J Cardiol. 2007;114:E401. DOIPubMed
  16. Tam  WO, Yew  WW, Yam  WC, Yuen  KY, Wong  PC, Tse  TF. Pacemaker infections due to rapidly growing mycobacteria: further experience. Int J Tuberc Lung Dis. 2007;11:118.PubMed
  17. Chrissoheris  MP, Kadakia  H, Marieb  M, Libertin  C. Pacemaker pocket infection due to Mycobacterium goodii: case report and review of the literature. Conn Med. 2008;72:757.PubMed
  18. Al Soub  H, Al Maslamani  M, Al Khuwaiter  J, El Deeb  Y, Abu Khattab  M. Myocardial abscess and bacteremia complicating Mycobacterium fortuitum pacemaker infection: case report and review of the literature. Pediatr Infect Dis J. 2009;28:10324. DOIPubMed
  19. Marchandin  H, Battistella  P, Calvet  B, Darbas  H, Frapier  JM, Jean-Pierre  H, Pacemaker surgical site infection caused by Mycobacterium goodii. J Med Microbiol. 2009;58:51720. DOIPubMed
  20. van Duin  D, Goldfarb  J, Schmitt  SK, Tomford  JW, Tuohy  MJ, Hall  GS. Nontuberculous mycobacterial blood stream and cardiac infections in patients without HIV infection. Diagn Microbiol Infect Dis. 2010;67:28690. DOIPubMed
  21. Karnam  S, Alla  VM, Kwon  J, Harbert  T, Sharma  A, Airey  K, Mycobacterium phlei, a previously unreported cause of pacemaker infection: thinking outside the box in cardiac device infections. Cardiol J. 2011;18:68790. DOIPubMed
  22. Amraoui  S, Texier-Maugein  J, Bordachar  P. PET scan in suspected but unproven pacemaker endocarditis. Arch Cardiovasc Dis. 2012;105:1256. DOIPubMed
  23. Sharma  H, Keshavan  A, Little  MA, Cross  J, Lipman  MC, Talukdar  S, Fortuitous vasculitis. Ren Fail. 2012;34:37882. DOIPubMed
  24. Hooda  A, Pati  PK, John  B, George  PV, Michael  JS. Disseminated Mycobacterium chelonae infection causing pacemaker lead endocarditis in an immunocompetent host. BMJ Case Rep. 2014;2014:pii: bcr201406042.
  25. Li  J, Sexton  D, Mick  N, Nettles  R, Fowler  V, Ryan  T Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30:6338. DOIPubMed
  26. Amin  M, Gross  J, Andrews  C, Furman  S. Pacemaker infection with Mycobacterium avium complex. Pacing and clinical electrophysiology. Pacing Clin Electrophysiol. 1991;14:1524. DOIPubMed
  27. Katona  P, Wiener  I, Saxena  N. Mycobacterium avium–intracellulare infection of an automatic implantable cardioverter defibrillator. Am Heart J. 1992;124:13801. DOIPubMed
  28. Doherty  JG, Rankin  R, Kerr  F. Miliary tuberculosis presenting as infection of a pacemaker pulse-generator pocket. Scott Med J. 1996;41:201.PubMed
  29. Hellwig  T, Ou  P, Offredo  C, Stephany  D, Bonnet  D, Sidi  D. Unusual chronic pacemaker infection by Mycobacterium tuberculosis in a pediatric patient. J Thorac Cardiovasc Surg. 2005;130:9378. DOIPubMed
  30. Kestler  M, Reves  R, Belknap  R. Pacemaker wire infection with Mycobacterium tuberculosis: a case report and literature review. Int J Tuberc Lung Dis. 2009;13:2724.PubMed
  31. Luckie  M, Zaidi  A, Woodhead  M, Garratt  C. Mycobacterium tuberculosis causing infection of an implantable biventricular defibrillator. Indian J Tuberc. 2010;57:2135.PubMed
  32. Stone  DR, Estes  NA III, Klempner  MS. Mycobacterium bovis infection of an implantable defibrillator following intravesical therapy with bacille Calmette-Guerin. Clin Infect Dis. 1993;16:8256. DOIPubMed
  33. Kumar  A, Agrawal  T. A study of unusual pacemaker infection by mycobacterium tuberculosis in Indian patients. Indian Pacing Electrophysiol J. 2014;14:2916.PubMed
  34. Wallace  RJ Jr, Musser  JM, Hull  SI, Silcox  VA, Steele  LC, Forrester  GD, Diversity and sources of rapidly growing mycobacteria associated with infections following cardiac surgery. J Infect Dis. 1989;159:70816. DOIPubMed
  35. Wallace  RJ Jr, Steele  LC, Labidi  A, Silcox  VA. Heterogeneity among isolates of rapidly growing mycobacteria responsible for infections following augmentation mammaplasty despite case clustering in Texas and other southern coastal states. J Infect Dis. 1989;160:2818. DOIPubMed
  36. Uslan  DZ, Kowalski  TJ, Wengenack  NL, Virk  A, Wilson  JW. Skin and soft tissue infections due to rapidly growing mycobacteria: comparison of clinical features, treatment, and susceptibility. Arch Dermatol. 2006;142:128792. DOIPubMed
  37. El Helou  G, Hachem  R, Viola  GM, El Zakhem  A, Chaftari  AM, Jiang  Y, Management of rapidly growing mycobacterial bacteremia in cancer patients. Clin Infect Dis. 2013;56:8436. DOIPubMed
  38. Nash  KA, Zhang  Y, Brown-Elliott  BA, Wallace  RJ Jr. Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum. J Antimicrob Chemother. 2005;55:1707. DOIPubMed
  39. Schembri  S, Williamson  PA, Short  PM, Singanayagam  A, Akram  A, Taylor  J, Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ. 2013;346:f1235. DOIPubMed
  40. Lapi  F, Wilchesky  M, Kezouh  A, Benisty  JI, Ernst  P, Suissa  S. Fluoroquinolones and the risk of serious arrhythmia: a population-based study. Clin Infect Dis. 2012;55:145765. DOIPubMed

Top

Figure
Tables

Top

Follow Up

Earning CME Credit

To obtain credit, you should first read the journal article. After reading the article, you should be able to answer the following, related, multiple-choice questions. To complete the questions (with a minimum 75% passing score) and earn continuing medical education (CME) credit, please go to http://www.medscape.org/journal/eid. Credit cannot be obtained for tests completed on paper, although you may use the worksheet below to keep a record of your answers. You must be a registered user on Medscape.org. If you are not registered on Medscape.org, please click on the “Register” link on the right hand side of the website to register. Only one answer is correct for each question. Once you successfully answer all post-test questions you will be able to view and/or print your certificate. For questions regarding the content of this activity, contact the accredited provider, CME@medscape.net. For technical assistance, contact CME@webmd.net. American Medical Association’s Physician’s Recognition Award (AMA PRA) credits are accepted in the US as evidence of participation in CME activities. For further information on this award, please refer to http://www.ama-assn.org/ama/pub/about-ama/awards/ama-physicians-recognition-award.page. The AMA has determined that physicians not licensed in the US who participate in this CME activity are eligible for AMA PRA Category 1 Credits™. Through agreements that the AMA has made with agencies in some countries, AMA PRA credit may be acceptable as evidence of participation in CME activities. If you are not licensed in the US, please complete the questions online, print the certificate and present it to your national medical association for review.

Article Title:
Patient Report and Review of Rapidly Growing Mycobacterial Infection after Cardiac Device Implantation

CME Questions

1. Your patient is a 65-year-old man recently implanted with a cardiac implantable electronic device (CIED) in whom mycobacterial infection is suspected. According to the case report and review by Phadke and colleagues, which of the following statements about the clinical and etiologic considerations regarding mycobacterial CIED infections is correct?

A.        Most mycobacterial CIED infections are slow growing

B.        CIED infections are not usually evident until at least 1 year after last manipulation

C.        Device-related endocarditis has not been reported

D.        Of 33 cases, 23 (70%) were due to rapidly growing mycobacteria (RGM) species including Mycobacterium fortuitum, 8 from M. tuberculosis complex, and 2 from M. avium complex

2. According to the case report and review by Phadke and colleagues, which of the following statements about antibiotic resistance of CIED infections due to RGM is correct?

A.        Extended incubation of routine cultures or dedicated mycobacterial culture is unnecessary

B.        The Clinical and Laboratory Standards Institute recommends routine broth microdilution susceptibility testing of all RGM isolates against amikacin, cefoxitin, ciprofloxacin, clarithromycin, doxycycline, imipenem, and sulfamethoxazole

C.        Current guidelines recommend therapy with only 1 drug for a period of several weeks for optimal results

D.        The M. fortuitum group is usually thought to be the most antibiotic resistant

3. According to the case report and review by Phadke and colleagues, which of the following statements about management of CIED infections due to RGM is correct?

A.        Macrolide-based regimens are the recommended therapy of choice for serious M. fortuitum infection

B.        Device removal is unnecessary

C.        Clinicians should be aware of the arrhythmogenicity of the antimicrobials traditionally recommended for infections arising from these organisms

D.        Newer antimicrobials have even greater direct arrhythmogenic effects

Activity Evaluation

1. The activity supported the learning objectives.

Strongly Disagree

Strongly Agree

1

2

3

4

5

2. The material was organized clearly for learning to occur.

Strongly Disagree

Strongly Agree

1

2

3

4

5

3. The content learned from this activity will impact my practice.

Strongly Disagree

Strongly Agree

1

2

3

4

5

4. The activity was presented objectively and free of commercial bias.

Strongly Disagree

Strongly Agree

1

2

3

4

5

Top

Cite This Article

DOI: 10.3201/eid2203.150584

Related Links

Table of Contents – Volume 22, Number 3—March 2016

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Varun K. Phadke, 49 Jesse Hill Jr. Dr, Atlanta, GA 30303, USA

Send To

character(s) remaining.

Comment submitted successfully, thank you for your feedback.

Top

Page created: February 16, 2016
Page updated: February 16, 2016
Page reviewed: February 16, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external